Allspring Global Investments’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Allspring Global Investments’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,354	Closed	-$30.9K	–	2925
2023 Q1	$30.9K	Sell	7,354 -174,437	-96%	-$905K	﹤0.01%	2418
2022 Q4	$1.09M	Sell	181,791 -921	-0.5%	-$5.03K	﹤0.01%	1409
2022 Q3	$1.06M	Buy	+182,712	New	+$1.14M	﹤0.01%	1417

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Allspring Global Investments's CTIC Position: Q2 2023 in Review

Allspring Global Investments sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 7,354 shares — an estimated $30.9K sold.

Allspring Global Investments first reported a position in CTIC in Q3 2022 and held it in 3 quarters. The position peaked at $1.09M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Allspring Global Investments reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Allspring Global Investments sold 7,354 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $30.9K.
Allspring Global Investments first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 3 quarters.
Allspring Global Investments's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.09M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.